Hospital Anxiety and Depression Scale (HADS) score trends among testicular cancer survivors: A longitudinal study.

Authors

Khalid Alkhatib

Khalid Y. Alkhatib

University of Pennsylvania, Philadelphia, PA

Khalid Y. Alkhatib , Daniel Roberson , Ruchika Talwar , Hanna Jia , Katherine Nathanson , S. Bruce Malkowicz , Thomas J. Guzzo , Phillip Pierorazio , Linda A. Jacobs , David J. Vaughn

Organizations

University of Pennsylvania, Philadelphia, PA

Research Funding

No funding received
None.

Background: The rarity of testicular germ cell tumors, in conjunction with the young age of its patients, makes it challenging to study its long-term adverse effects. We sought to investigate the changes in Hospital Anxiety and Depression Scale (HADS) scores over time in our institutional cohort of testicular cancer (TC) survivors, hypothesizing that anxiety and depression indices will improve over time, and specifically after treatment completion. Methods: A longitudinal analysis of TC survivors at the University of Pennsylvania between 2013 and 2020, quality of life metrics were measured annually during routine clinic visits. A validated HADS score was utilized to calculate indices of anxiety and depression. Multivariable linear mixed-effects regression models adjusted for pathology type, stage, treatment type, age, marital status, education, income, insurance, employment status, living situation, and time from diagnosis to first survey administration were used to calculate the mean predicted HADS, HADS-Anxiety, and HADS-Depression scores. ANOVA was used to test for parallelism and changes between survey scores. Each item is rated on a 4-point scale (ranging from 0 = no not at all, to 3 = yes definitely), for a total score ranging from 0-21 for each sub-scale with a cut-off point of 8/21 for anxiety or depression. Results: A total of 353 patients were included in the study. Baseline mean scores were 7.3, 4.9, and 2.4 for HADS overall, HADS-Anxiety, and HADS-Depression, respectively. Mean scores did not change over time, ANOVA testing of p=0.84, p=0.78, and p=0.0.65 for overall HADS, HADS-Anxiety, and HADS-Depression, respectively. Stratification by pathology, stage, or treatment did not show any significant interaction. Conclusions: Our data demonstrates that there was no significant change over time in HADS scores, thus considering the risks associated with depression and anxiety, such as suicide, it is essential to consider early referrals to psychiatric services. Our results are from a single institution, limited by a small sample size, and data lacks granularity, including mental health history. Nonetheless, our findings serve as a framework for future prospective studies of TC survivors.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Germ Cell/Testicular Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5042)

DOI

10.1200/JCO.2023.41.16_suppl.5042

Abstract #

5042

Poster Bd #

136

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Genitourinary Cancers Symposium

Impact of chemotherapy on anxiety, depression, and suicidality amongst testicular cancer survivors.

First Author: Tyler J. Nelson

First Author: Charles Stewart Kamen

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Examining the prevalence of anxiety and depression in surgical oncology patients: Results of a prospective cohort study.

First Author: Judy Li